Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Denny Kwon represents public and private companies, private equity firms, and investment banks in a wide range of M&A transactions. In his 20 years, Mr. Kwon has advised clients in strategic transactions in the technology, life sciences and other industries, and has become a trusted advisor to some of the most active acquirers in the technology industry. His broad experience includes the acquisition of public and private companies, divisions, and other assets structured as mergers, stock purchases, asset purchases, acqui-hires, mergers of equals, joint ventures, spinoffs, strategic investments, leveraged buy-outs, going-private transactions, tender offers, unsolicited offers, and proxy contests.

  • Pharmacyclics in its $21 billion acquisition by AbbVie.
  • Astellas in its $3 billion acquisition of Audentes.
  • MuleSoft in its $6.5 billion acquisition by Salesforce.
  • AppDynamics in its $3.7 billion acquisition by Cisco Systems.
  • McAfee in its $7.7 billion acquisition by Intel.
  • 3PAR in its original agreement to be acquired by Dell for $1.7 billion acquisition, in the unsolicited acquisition proposals from Hewlett-Packard, and in its $2.4 billion acquisition by Hewlett-Packard.

Buy-Side Representations in Public Company Transactions

  • MaxLinear in its $700 million acquisition of Exar.
  • Coherent in its $942 million acquisition of ROFIN-SINAR Technologies.
  • Gilead Sciences in its $510 million acquisition of YM Biosciences.
  • Total in its $1.4 billion negotiated tender offer to acquire 60 percent of the outstanding shares of SunPower.
  • Microchip Technology in its $939 million acquisition of Standard Microsystems; $394 million acquisition of Supertex; and $300 million acquisition of Silicon Storage Technology through a go-shop process and subsequent competitive bidding process versus Cerberus Capital Management.
  • Seagate Technology in its $374 million acquisition of Xyratex.

Sell-Side Representations in Public Company Acquisitions

  • OmniVision Technologies in its $1.9 billion acquisition by Hua Capital Management, CITIC Capital, and GoldStone Investment.
  • Astex Pharmaceuticals in its $866 million acquisition by Otsuka Pharmaceutical.
  • Isilon Systems in its $2.5 billion acquisition by EMC.
  • 3Com in its $3.3 billion acquisition by Hewlett-Packard.
  • Varian in its $1.5 billion acquisition by Agilent Technologies.

Buy-Side Representations in Private Company Acquisitions 

  • ServiceNow in 10 acquisitions since 2016.
  • Salesforce in five acquisitions since 2016, including its $700 million acquisition of Krux.   
  • Nutanix in six acquisitions since 2016.
  • Numerous other public and private companies in their acquisitions, including BloomReach, E2open, ForeScout Technologies, Instacart, MINDBODY, MongoDB, Mozilla, Micron Technology, MuleSoft, NETGEAR, Palo Alto Networks, Quotient Technology, Talend, Zscaler, and Zynga.

Sell-Side Representations in Private Company Acquisitions

  • Velocloud in its acquisition by VMware.
  • Cyence in its $275 million acquisition by Guidewire Software.
  • Silego Technology in its acquisition by Dialog Semiconductor for up to $306.4 million.
  • Recommind in its $165 million acquisition by OpenText.
  • Ravello Systems in its acquisition by Oracle.
  • Vormetric in its $400 million acquisition by Thales.
  • Accel Partners (lead investor) in PayPal's $800 million acquisition of Braintree.
  • hybris in its > $1 billion acquisition by SAP.
  • iWatt in its acquisition by Dialog Semiconductor for up to $345 million.
  • Calistoga Pharmaceuticals in its acquisition by Gilead Sciences for up to $600 million.
  • CoreValve in its acquisition by Medtronic for up to $850 million.

Private Equity Transactions

  • Capsilon in its recapitalization and investment by Francisco Partners.
  • E2open in its $273 million acquisition by Insight Venture Partners.
  • Aicent (a TA Associates portfolio company) in its $290 million acquisition by Syniverse; and in its recapitalization and investment by TA Associates.
  • Service Repair Solutions (a Warburg Pincus portfolio company) in its acquisition by Welsh, Carson, Anderson & Stowe.   
  • Skullcandy in connection with its recapitalization and investment by Goode Partners.